MF
RARE icon

Magnetar Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Magnetar Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,147
Closed -$404K – 1101
2025
Q1 		$404K Buy
11,147
+4,368
+64% +$182K 0.01% 507
2024
Q4 		$285K Buy
+6,779
New +$336K 0.01% 485
2022
Q4 		– Sell
-12,583
Closed -$521K – 914
2022
Q3 		$521K Buy
+12,583
New +$647K 0.01% 814
2020
Q2 		– Sell
-11,096
Closed -$493K – 560
2020
Q1 		$493K Buy
+11,096
New +$576K 0.01% 279

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Magnetar Financial's RARE Position: Q2 2025 in Review

Magnetar Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 11,147 shares — an estimated $404K sold.

Magnetar Financial first reported a position in RARE in Q1 2020 and held it in 4 quarters. The position peaked at $521K in Q3 2022. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

  • Magnetar Financial reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Magnetar Financial sold 11,147 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $404K.
  • Magnetar Financial first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and held it in 4 quarters.
  • Magnetar Financial's Ultragenyx Pharmaceutical position peaked at $521K in Q3 2022.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Magnetar Financial's 13F filing for Q2 2025, filed 12 Aug 2025.